FAQs & Information About Our Clinical Trials
Before agreeing to participate in a clinical trial, you should have a very good understanding of the benefits and risks of doing so. The following FAQ might be helpful to you in making your decision. The US Government also has a good website that might help answer your clinical research questions regarding medical studies (http://clinicaltrials.gov/ct2/info/understand).
You may also want to talk to your own health care provider, the investigator or a study coordinator of the particular study. You may call CenExel Sherman Oaks directly at (818)-990-2671 if you have any questions or concerns, or would like to request medical study information.
Clinical research involves testing an investigational drug or device in humans. Each clinical trial must use a protocol that has been written according to government regulations and that is also approved by the company sponsoring the study. An investigational drug may be:
- a drug that has not yet been approved for marketing (i.e., a drug that is not allowed to be sold)
- a drug that is currently on the market but that is being studied for a non-approved indication or is being studied in a new route of administration, strength, or formulation;
- a drug that is being sold on the market by one company but that is being considered for in-license or acquisition by another company;
a drug that contains known and established ingredients but has not yet been marketed by the company; - a drug that is currently on the market but is being studied in a population for which the drug has not yet been approved, such as in children or in elderly patients.
Before an investigational drug or device can be studied in humans, its safety and effectiveness is carefully studied in the laboratory. However, this early research cannot predict how safe and effective the drug will be in humans. With any new treatment there may be benefits as well as known and unknown risks. Clinical research trials are conducted to determine whether promising new treatments will be safe and effective for patients.
Phase II studies help determine how safe and effective a drug is, common short-term side effects of the drug, pharmacokinetic effects of the drug (i.e., the amount of drug that gets into the bloodstream, how quickly it gets there, and how long it stays there) and pharmacodynamic effects of the drug (i.e., the effects of the drug on the body). These studies involve a larger group of participants (e.g., 100 to 200 people) and are usually conducted in participants who have the medical condition for which the drug is being studied. These studies are used to identify the dose range of the drug that will be tested in subsequent larger studies (i.e., Phase III studies).
Phase III studies provide additional information about safety and efficacy when the drug is used in the way it is intended to be marketed. These studies are initiated only after earlier studies have demonstrated that there is an acceptable risk to benefit profile (i.e., the risk of taking the drug is outweighed by the potential benefit of the drug to the participant). These large studies are usually conducted at many different study centers; up to 10 to 30 study centers and between 500 and 5,000 participants may be included.. These studies are used to confirm the indication and best dosage for the drug.
Phase IV studies are conducted after the drug is available for sale (i.e., post-marketing studies) and they evaluate how safe and effective the drug is when exposed to the “real” population. These studies evaluate parameters such as different formulations, dosages, treatment durations, and drug interactions. The Food and Drug Administration (FDA) may require a company to conduct certain Phase IV studies as a provision for product approval. These studies may include new age groups, various races and other types of participants. These studies are useful for detecting and defining previously unknown or inadequately quantified adverse events and related risk factors. The size of these studies is broad and can range from less than 100 to over 20,000 participants.
People who participate in clinical trials are among the first to receive new research treatments before they become widely available. Sometimes these people have the first chance to benefit from a cutting-edge treatment. However, there is no way to know whether an investigational treatment will be effective for a participant. (Even standard treatments, although effective in many participants, do not guarantee benefits for everyone.) Some people in a study may not receive the active treatment and instead will receive a placebo (i.e., a sugar pill). Although all participants in clinical trials are carefully monitored both during and after conclusion of the trial, there are always known and unknown risks associated with new treatments. Participants should decide whether or not to participate in a study only after they understand both the potential risks and benefits.
Some clinical trials involve more tests and doctor visits than you would normally have for your illness or condition. Your participation will be most successful if you carefully follow all instructions you are given and stay in contact with the research staff.
